Triple-Drug attack on Hard-to-Treat stomach cancer shows promise in early trial
NCT ID NCT07176312
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times
Summary
This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer from growing for at least 12 months. All participants receive the same treatment, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanidatamab (a targeted antibody), pembrolizumab (an immunotherapy), and chemotherapy (mFOLFOX)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with HER2 and PD-L1 positive metastatic gastroesophageal cancer, potentially improving how long they live without the disease getting worse.
What could go wrong
This is an early Phase II trial with only 80 participants and no comparison group, so results may not be definitive. The combination of three drugs may cause significant side effects, and not all patients will respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Klinik Altona
RECRUITINGHamburg, Germany
Contact
-
Charité CVK
RECRUITINGBerlin, Germany
Contact
-
Evang. Kliniken Essen Mitte
RECRUITINGEssen, Germany
Contact
-
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
RECRUITINGHamburg, 20249, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johannes Wesling Klinikum Minden
NOT_YET_RECRUITINGMinden, Germany
Contact
-
Klinikum Bielefeld
RECRUITINGBielefeld, Germany
Contact
-
Klinikum Wolfsburg
NOT_YET_RECRUITINGWolfsburg, Germany
-
Klinikum rechts der Isar der TU München
RECRUITINGMünchen, Germany
-
Krankenhaus Barmherzige Brüder Regensburg
RECRUITINGRegensburg, Germany
-
Krankenhaus Nordwest
RECRUITINGFrankfurt, Germany
Contact
-
LMU Klinikum München Großhadern
NOT_YET_RECRUITINGMünchen, Germany
Contact
-
MVZ für Hämatologie und Onkologie Ravensburg
RECRUITINGRavensburg, Germany
-
St. Anna Hospital Herne
RECRUITINGHerne, Germany
Contact
-
Städtisches Klinikum Dresden
NOT_YET_RECRUITINGDresden, Germany
Contact
-
Universitätsklinikum Göttingen
NOT_YET_RECRUITINGGöttingen, Germany
Contact
-
Universitätsklinikum Hamburg Eppendorf
RECRUITINGHamburg, Germany
Contact
-
Universitätsklinikum Jena
RECRUITINGJena, Germany
Contact
-
Universitätsklinikum Ulm
RECRUITINGUlm, Germany
Contact
-
Universitätsmedizin Mainz
NOT_YET_RECRUITINGMainz, Germany
Contact
-
Vivantes Klinikum im Friedrichshain
RECRUITINGBerlin, Germany